Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Sermorelin vs Somapacitan (Sogroya)
An educational, source-based comparison of Sermorelin and Somapacitan (Sogroya) — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic 29-amino-acid analog representing the active fragment of endogenous GHRH. Stimulates the pituitary to release GH in a physiologic, pulsatile pattern. Previously FDA-approved (Geref) for pediatric GH deficiency diagnosis before discontinuation for commercial reasons.
- Adult GH deficiency
- Pediatric short stature (historical)
- Sleep quality and body composition in aging
- • No longer commercially available as an FDA-approved drug; available via compounding.
- • Requires physician oversight.
- • Banned in competitive sport.
Once-weekly growth hormone analog for adults and children with GHD.
GH analog with a non-covalent albumin-binding side chain that extends half-life, enabling once-weekly subcutaneous administration with sustained IGF-1 elevation.
- Adult growth hormone deficiency
- Pediatric GH deficiency
- • FDA-approved.
- • Monitor glucose; injection-site reactions possible.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Sermorelin | Sermorelin in adult growth hormone deficiency | Endocrine Practice | 2010 | Reviewed efficacy on body composition, energy, and sleep markers. |
| Somapacitan (Sogroya) | REAL trials | JCEM | 2020 | Comparable body composition and IGF-1 response to daily somatropin. |
Side-effect & safety grid
- No longer commercially available as an FDA-approved drug; available via compounding.
- Requires physician oversight.
- Banned in competitive sport.
- FDA-approved.
- Monitor glucose; injection-site reactions possible.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Sermorelin vs Somapacitan (Sogroya) — Key differences
- Class: Sermorelin is classified as Growth Hormone Axis, while Somapacitan (Sogroya) is GH Analog · Endocrine.
- Primary research focus: Sermorelin — adult gh deficiency; Somapacitan (Sogroya) — adult growth hormone deficiency.
- Tag: Growth hormone vs FDA-Approved · Endocrine.